Key Takeaways
- • Miles Wang, an OpenAI researcher specializing in AI-driven scientific and biological discovery, is launching a dedicated AI drug discovery startup valued at $2 billion in pre-money valuation, with talks underway to raise approximately $200 million.
- • Lightspeed Venture Partners is in discussions to lead the funding round; multiple OpenAI researchers are expected to join Wang at the new venture, though deal terms remain subject to change.
- • Wang's startup is positioning itself in an increasingly competitive AI drug discovery market, focusing on identifying new therapeutic uses for existing FDA-approved drugs—a strategy that accelerates time-to-revenue compared to de novo drug development.
- • The funding discussions reflect sustained institutional capital interest in AI applications for life sciences, following recent major fundraising rounds: Chai Discovery raised $400 million at a $3.8 billion valuation in July 2026, and Google DeepMind spinout Isomorphic Labs closed a $2.1 billion Series B in May 2026.
- • Wang joined OpenAI in 2024 after leaving Harvard University, where he was pursuing a bachelor's degree in computer science, and is now among the latest senior AI talent to depart the company for specialized biotech applications.
Summary
Miles Wang, an OpenAI researcher whose work centers on accelerating scientific discovery through artificial intelligence, is in advanced talks to establish a new startup focused exclusively on AI-driven drug discovery. The venture carries a $2 billion pre-money valuation, with fundraising discussions targeting approximately $200 million in Series A capital. Lightspeed Venture Partners is reportedly in discussions to lead the round, though talks remain ongoing and final terms have not been finalized. Wang has indicated that certain details in initial reporting are inaccurate but has not publicly specified corrections.
The startup reflects a strategic pivot toward a higher-margin application of AI technology within pharmaceutical development: identifying new therapeutic indications for existing, FDA-approved medications rather than pursuing novel drug discovery from compound zero. This approach significantly compresses development timelines and regulatory risk, as candidate molecules have already completed safety testing. Several additional OpenAI researchers are expected to join Wang in this venture, marking a notable departure of specialized talent from the ChatGPT developer.
Wang's initiative arrives amid robust institutional interest in AI-enabled drug discovery. Chai Discovery, a two-year-old competitor, announced a $400 million Series A funding round at a $3.8 billion post-money valuation on July 15, 2026—one day after Wang's discussions became public. Chai's co-founder, Josh Meier, similarly transitioned from OpenAI to biotech. Google DeepMind's Isomorphic Labs, which also develops AI models for molecular prediction and drug discovery, closed a $2.1 billion Series B in May 2026. These data points underscore sustained venture capital appetite for AI applications in life sciences, despite competitive saturation.
Wang joined OpenAI in 2024 following his departure from Harvard University, where he was enrolled in a computer science bachelor's degree program. His trajectory exemplifies the pipeline through which foundational AI research talent is being redirected toward domain-specific applications in regulated industries. The timing of his departure and the valuation attached to his nascent venture suggest that elite AI researchers command significant capital multiples when establishing specialized ventures, particularly in high-stakes sectors like pharmaceutical development.
The startup reflects a strategic pivot toward a higher-margin application of AI technology within pharmaceutical development: identifying new therapeutic indications for existing, FDA-approved medications rather than pursuing novel drug discovery from compound zero. This approach significantly compresses development timelines and regulatory risk, as candidate molecules have already completed safety testing. Several additional OpenAI researchers are expected to join Wang in this venture, marking a notable departure of specialized talent from the ChatGPT developer.
Wang's initiative arrives amid robust institutional interest in AI-enabled drug discovery. Chai Discovery, a two-year-old competitor, announced a $400 million Series A funding round at a $3.8 billion post-money valuation on July 15, 2026—one day after Wang's discussions became public. Chai's co-founder, Josh Meier, similarly transitioned from OpenAI to biotech. Google DeepMind's Isomorphic Labs, which also develops AI models for molecular prediction and drug discovery, closed a $2.1 billion Series B in May 2026. These data points underscore sustained venture capital appetite for AI applications in life sciences, despite competitive saturation.
Wang joined OpenAI in 2024 following his departure from Harvard University, where he was enrolled in a computer science bachelor's degree program. His trajectory exemplifies the pipeline through which foundational AI research talent is being redirected toward domain-specific applications in regulated industries. The timing of his departure and the valuation attached to his nascent venture suggest that elite AI researchers command significant capital multiples when establishing specialized ventures, particularly in high-stakes sectors like pharmaceutical development.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.